A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia.

Trial Profile

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2014

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Aspirin; Clopidogrel; Laropiprant
  • Indications Dyslipidaemias; Embolism and thrombosis; Hypercholesterolaemia
  • Focus Pharmacodynamics
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 01 Nov 2011 Results published in Platelets.
    • 28 Apr 2010 Status changed from recruiting to completed vas reported by ClinicalTrials.gov.
    • 28 Apr 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top